Spectrum’s Zevalin Still Living In Rituxan’s Shadow, FDA Advertising Letter Shows
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA citations of Rituxan comparisons in a promotion for Zevalin throw added salt on old wounds for drug that has taken backseat to Rituxan’s blockbuster story.
You may also be interested in...
Promotions For Black-Box Drugs Aren’t Specific Enforcement Targets, FDA Says
FDA advertising enforcement does not preference black-box drugs despite risk-based approach prioritizing products with significant risks; nor are drugs with small patient populations exempt from risk-based approach.
Cancer Drug Zevalin May Finally Thrive Under Spectrum
The small oncology company may be able to succeed with the non-Hodgkin lymphoma drug where others have failed.
Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says
Updated draft guidance on promotion of biologic reference products, biosimilars and interchangeable biosimilars offers another indication of the US’s push to do away with the interchangeability designation.